MedTrace Logo

SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI

NCT01182376 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2016-02-19

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to demonstrate how dronedarone (Multaq®) may aid in the slowing of progression of left atrial and ventricular fibrosis in patients with atrial fibrillation as assessed by late gadolinium enhanced magnetic resonance imaging.

Conditions

Interventions

DRUG

dronedarone

Dronedarone will be prescribed by the patient's team according to established guidelines.

DRUG

Placebo

Placebo will be administered by the patient's team according to established guidelines.

Sponsors & Collaborators

Principal Investigators

  • Nassir F Marrouche, MD · University of Utah

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-12-31
Completion
2012-12-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01182376 on ClinicalTrials.gov